Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Insights from in vitro models in albinism
Author Affiliations & Notes
  • Brian Patrick Brooks
    Ophthalmic Genetics Branch, National Eye Inst/NIH, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Brian Brooks None
  • Footnotes
    Support  Supported by the intramural program of the National Eye Institute, NIH
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2802. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Brian Patrick Brooks; Insights from in vitro models in albinism. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2802.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Oculocutaneous albinism (OCA) is a genetically heterogeneous autosomal recessive condition characterized by reduced melanin pigment in the hair, skin and eyes, as well as developmental eye abnormalities (foveal hypoplasia, ganglion cell axon misrouting) that limit vision. The reason why reduced melanin in the retinal pigment epithelium (RPE)/choroid leads to these neural retinal abnormalities is unclear, but we postulate that one or more non-cell autonomous factors from the former are influencing development in the latter. Given that foveal development continues after birth, therapeutic intervention to normalize such factors early in life could potentially improve vision in OCA patients.

To investigate the molecular pathogenesis of albinism we have created RPE derived from induced pluripotent stem cells (iPSCs) from patients with two forms of albinism—OCA1A (due to mutations in TYROSINASE) and OCA2 (due to mutations in the P gene). We will review the morphologic and functional characteristics of this model, emphasizing differences in cell-cell adhesion, apical processes, and gene expression, with particular attention to druggable targets and potential biomarkers for clinical trials.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×